Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cisco Systems Inc (CSCO) vs Nuvalent Inc (NUVL) Price & Performance

Cisco Systems IncTrade
Nuvalent IncTrade

Price performance (Past 24H)

Key statistics

Cisco Systems Inc vs Nuvalent Inc — how do they compare? Cisco Systems Inc trades at $113.28 (market cap $461.50B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Cisco Systems Inc is far larger — about 47× Nuvalent Inc's market cap, and Cisco Systems Inc pays a 1.43% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.

CSCONUVL
Market Cap
$461.50B$9.81B
Volume
22,887,319
Sector
TechnologyTechnology
52-Week High
$130.00$123.96
52-Week Low
$66.20$72.16
Enterprise Value
$476.17B$8.52B
Dividend Yield
1.43%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cisco Systems Inc

Cisco Systems (CSCO) trades at $119.25, down 1.7% over 24 hours, with a bullish technical signal from moving averages and recent AI-driven news boosting sentiment. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.06 exceeding the $1.03 estimate. Financials show solid profitability with a 64.33% gross margin and $10.18B net income for 2025, though valuation ratios like P/E of 39.03 appear elevated. Analyst consensus is bullish with a $130.38 price target, supported by 38 buy ratings.

Outlook remains positive due to AI cybersecurity demand and partnerships, but risks include high debt levels and competitive pressures. The stock offers growth potential from tech infrastructure trends, yet investors should monitor execution on AI initiatives and macroeconomic headwinds that could impact networking spending.

Nuvalent Inc

Nuvalent (NUVL) trades at $123.94, showing minimal daily movement with a 0.03% gain. The stock is in focus following GSK's proposed acquisition at $124 per share, announced June 2026. Technically, the price is at the acquisition offer level with a bullish moving average signal but overbought RSI readings. Fundamentally, the company reports significant losses with negative ROE and ROA, while cash flow remains supported by financing activities.

The investment outlook is dominated by the pending acquisition, limiting upside beyond the offer price. Key risks include deal completion uncertainty and ongoing operational losses. Analyst sentiment is mixed with a slight hold bias, reflecting caution until transaction closure. Shareholder value hinges on successful deal execution amid financial challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cisco Systems Inc

Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.

Read more on CSCO

About Nuvalent Inc

Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.

Read more on NUVL